secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-09-10T20:07:55+00:00
Accession:  0001437749-26-030073
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed's neflamapimod Phase 2a nfvPPA data accepted as late-breaking oral at ISFTD 2026
--------------------------------------------------------------------------------

- Phase 2a trial of neflamapimod in nfvPPA completed enrollment with 25 participants.
- 12-week biomarker data from first 8 participants accepted as late-breaking oral at ISFTD 2026 (Oct 8-11, Philadelphia).
- Presentation will highlight NfL and GFAP biomarker results from at least 22 participants.
- nfvPPA has no approved treatments in US or EU; trial conducted at US and UK academic centers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926030073/0001437749-26-030073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926030073/crvo20260910_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-030073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer